Clinical Trial Update: A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease. [Phase 4]

View source ↗

Summary

This Phase 4 dose-conversion study of epoetin alfa in subjects with anemia of chronic kidney disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Chronic Kidney Disease
• Chronic Kidney Disease

Drugs mentioned

• Epogen (epoetin alfa)

Snippet

Sponsor: Ortho Biotech Products, L.P. | Conditions: Anemia, Chronic Renal Insufficiency | Phase 4 | Status: TERMINATED